First line triplet chemotherapy/BEV significantly improved clinical outcome of MCRC. KRAS/NRAS/BRAF mutations were evaluated by next generation sequencing (NGS) in MCRC patients treated with first line FIr-B/FOx.
KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy / Bruera, Gemma; Pepe, Francesco; Malapelle, Umberto; Pisapia, Pasquale; Mas, Antonella Dal; Di Giacomo, Daniela; Calvisi, Giuseppe; Troncone, Giancarlo; Ricevuto, Enrico. - In: ONCOTARGET. - ISSN 1949-2553. - 9:41(2018), p. 26279-26290. [10.18632/oncotarget.25180]
KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy
Pepe, Francesco;Malapelle, Umberto;Pisapia, Pasquale;Troncone, Giancarlo;
2018
Abstract
First line triplet chemotherapy/BEV significantly improved clinical outcome of MCRC. KRAS/NRAS/BRAF mutations were evaluated by next generation sequencing (NGS) in MCRC patients treated with first line FIr-B/FOx.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
